Takeda Pharmaceutical (TAK) Fundamental Analysis: Revenue, Earnings & Valuation

5.32 / 10

Netural

Fundamental evaluation presents moderate characteristics (5.3/10). Strengths encompass Fixed assets turnover ratio and Cost of sales ratio (%), however risks emerge in PB-ROE. This justifies moderate view.

Analysis Checks(9/10)

Total operating revenue (YoY growth rate %)

Value7.45

Score2/3

Weight1.08%

1M Return0.32%

Inventory turnover ratio

Value1.30

Score3/3

Weight-1.85%

1M Return-0.51%

PB-ROE

Value-0.69

Score1/3

Weight28.36%

1M Return7.72%

Fixed assets turnover ratio

Value2.32

Score2/3

Weight-2.57%

1M Return-0.77%

Interest coverage ratio (EBIT / Interest expense) (%)

Value2.07

Score2/3

Weight-3.62%

1M Return-1.10%

Diluted earnings per share (YoY growth rate %)

Value-26.25

Score2/3

Weight0.53%

1M Return0.16%

Operating revenue (YoY growth rate %)

Value7.45

Score2/3

Weight0.95%

1M Return0.28%

Cost of sales ratio (%)

Value34.49

Score3/3

Weight3.11%

1M Return0.82%

Asset-MV

Value1.36

Score3/3

Weight76.02%

1M Return14.80%

Net profit / Total profit (%)

Value61.77

Score2/3

Weight-2.03%

1M Return-0.60%

Is TAK undervalued or overvalued?

TAK scores 5.32/10 on fundamentals and holds a Fair valuation at present. Backed by its 2.96% ROE, 2.54% net margin, 77.32 P/E ratio, 1.20 P/B ratio, and -39.04% earnings growth, these metrics solidify its Netural investment rating.